MarkWide Research

Sale!

Metabolomics Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: July, 2022
No of Pages: 168
Delivery Format: PDF + Excel

$2,950.00

The global metabolomics market for biomarkers is expected to grow at around 12% CAGR over the forecast period. Metabolomics refers to the study on a large scale of small molecules. These molecules are commonly called metabolites. These small molecules and their interactions in a biological system are collectively known as the Metabolome. For decades, biomarkers have been made from metabolites. Metabolomics is used to detect sugar in the urine to diagnose diabetes. A growing number of biomarkers are being discovered through the study of metabolites, transforming healthcare and the life science industry.

Metabolomics is an effective tool because the concentrations of metabolites in tissues/cells and the primary biochemical activity are reflected in their metabolites. Metabolomics technology has made it possible to better diagnose, target the right therapeutic targets and predict disease development. Recent developments in instruments such as mass spectrometry and ultra-performance liquid Chromatography, high-resolution NMR spectroscopy, and bioinformatics have allowed for wider exposure to the Metabolome.

The market will see significant growth due to innovative developments in informatics, analytical technologies, and increased pharmaceutical and biotech R&D spending. Market growth will also be driven by other factors, such as the ongoing research into metabolomics biomarkers and the extensive use of metabolomics biomarkers in the detection of colorectal carcinoma. The market is also being driven by increased R&D spending in the biotech and pharmaceutical industries.

The market is being held back by a few factors. These include limitations in experimental and biological measurements, high capital costs for tools and instruments, and a shortage of qualified researchers. There are huge opportunities in the market due to the increasing demand for personalized medicine and drug development and large investments in metabolomics market research.

Segmental Outlook

The market for global metabolomics biomarkers is segmented based on technology, application, and end-user. The market can be divided by application into toxicological studies and drug testing. Technology can divide the market into NMR, mass spectrometry, chromatography, and others. The market can be divided by end-user into hospitals, diagnostic labs, and research centers.

The market is segmented based on technology, application, and end-users. The market can be divided into toxicological studies and drug testing. Market share is expected to be dominated by the drug testing segment. Market growth can be attributed to the widespread use of metabolomics biomarkers to discover new methods or drugs to treat chronic diseases like cancer, CVDs, and neurological disorders. Many small and medium-sized companies are also stepping up to develop metabolomics biomarkers to diagnose chronic diseases. This is fueling the segmental market growth.

Regional Outlooks

The market for metabolomics biomarkers is analyzed based on which geographical regions contribute most to its growth. The market can be divided by geography into North America (Europe, Asia-Pacific, and the Rest of the World). North America led the market and will continue to be the dominant country in the future. Regional growth is due to increased funding for biomarkers development and increased usage of biomarkers within drug discovery & treatment.

Outlook for Market Players

BG Medicine Inc., Agilent, Biomark Diagnostics Inc., Merck KGaA, Merck KGaA, Waters, Metabolomic Diagnostics Ltd., Stemina Biomarker Discovery, Inc., Thermo Fisher Scientific Inc. are some of the major players in the metabolomics market. Companies are creating innovative metabolomics biomarkers for the market to help develop treatment and diagnostics for metabolic and infectious diseases. These companies also use different marketing strategies to stay relevant in the market. In 2018, Agilent Technologies, Inc. formed a partnership to launch a new integrated solution that combines cellular metabolic analysis with imaging technologies. This would combine the Agilent Seahorse/XFe24 Analyzers and the BioTekCytation1 Cell Imaging Multi-Mode Reader. This collaboration will allow the company to advance scientific discovery through technological innovation.

This Report Covers

  • Market value analysis for 2020 and projections to 2027.
  • For each market segment, annual market revenues ($million)
  • Analysis of the major geographic regions by country.
  • Companies that are key players in the global Metabolomics market for biomarkers. The report also contains information about new product launches and other relevant news based on available data.
  • Analyze business strategies to identify key market segments that are poised for strong growth in the future.
  • Analyze of market entry strategies and market expansion strategies
  • Strategies to be competitive by identifying who is where in the market

Metabolomics Market Report Scope and Segmentation

ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

Metabolomics Market Segmentation

By Product & Services

  • Metabolomics instruments
    • Separation tools
      • High-performance liquid chromatography (HPLC)
      • Gas chromatography (GC)
      • Ultra-performance liquid chromatography (UPLC)
      • Capillary electrophoresis (CE)
    • Detection tools
      • Mass spectrometry
      • Nuclear magnetic resonance spectroscopy (NMR)
      • Surface-based mass analysis
  • Metabolomics bioinformatics tools and services
    • Bioinformatics tools & databases
    • Bioinformatics services

By Application

  • Biomarker discovery
  • Drug discovery
  • Toxicology testing
  • Nutrigenomics
  • Functional genomics
  • Personalized medicine
  • Others

By Clinical Indication

  • Cancer
  • Cardiovascular disorders
  • Neurological disorders
  • Inborn errors of metabolism
  • Others

key Players covered:

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Waters Corporation
  • Danaher Corporation
  • Shimadzu Corporation
  • Biocrates Life Sciences AG
  • Bio-Rad Laboratories
  • Bruker Corporation,
  • Human Metabolome Technologies
  • Leco Corporation
  • Metabolon
  • Others

Global Metabolomic Market by Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa
    • Rest of MEA

Available customizations

You can customize the market data according to your client’s requirements. These customization options are not limited to the report:

  • Additional breakdown of a country relative to its region
  • Additional information about other countries
  • Additional segment
  • Analyze and profiles of other market players

 

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Metabolomics Biomarker Market
  • Recovery Scenario of Global Metabolomics Biomarker Market

1.1. Research Methods and Tools1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global Metabolomics Biomarker Market By Application
5.1.1. Toxicological Studies
5.1.2. Drug Testing
5.1.3. Diagnosis
5.2. Global Metabolomics Biomarker Market BY Technology
5.2.1. Chromatography
5.2.2. Nuclear Magnetic Resonance (NMR)
5.2.3. Mass Spectrometry
5.2.4. Others
5.3. Global Metabolomics Biomarker By End-User
5.3.1. Hospitals
5.3.2. Diagnostic Labs & Research Centers

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. AB Sciex LLC
7.2. Agilent Technologies, Inc.
7.3. BG Medicine Inc.
7.4. Biocrates Life Sciences AG
7.5. Biomark Diagnostics Inc.
7.6. Bruker Corp.
7.7. Chenomx Inc.
7.8. Creative Proteomics
7.9. Evotec A.G.
7.10. Human Metabolome Technologies America, Inc.
7.11. Merck KGaA
7.12. Metabolomic Diagnostics Ltd.
7.13. Metabolon, Inc.
7.14. Metanomics Health Gmbh
7.15. Nightingale Health Ltd.
7.16. Ovid Therapeutics Inc.
7.17. OWL Metabolomics
7.18. Prosciento, Inc.
7.19. Sidmap LLC
7.20. Stemina Biomarker Discovery, Inc.
7.21. System Biosciences, LLC
7.22. Thermofisher Scientific Inc.

Segmentation

Metabolomics Market Segmentation

By Product & Services

  • Metabolomics instruments
    • Separation tools
      • High-performance liquid chromatography (HPLC)
      • Gas chromatography (GC)
      • Ultra-performance liquid chromatography (UPLC)
      • Capillary electrophoresis (CE)
    • Detection tools
      • Mass spectrometry
      • Nuclear magnetic resonance spectroscopy (NMR)
      • Surface-based mass analysis
  • Metabolomics bioinformatics tools and services
    • Bioinformatics tools & databases
    • Bioinformatics services

By Application

  • Biomarker discovery
  • Drug discovery
  • Toxicology testing
  • Nutrigenomics
  • Functional genomics
  • Personalized medicine
  • Others

By Clinical Indication

  • Cancer
  • Cardiovascular disorders
  • Neurological disorders
  • Inborn errors of metabolism
  • Others

Major Companies

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Waters Corporation
  • Danaher Corporation
  • Shimadzu Corporation
  • Biocrates Life Sciences AG
  • Bio-Rad Laboratories
  • Bruker Corporation,
  • Human Metabolome Technologies
  • Leco Corporation
  • Metabolon
  • Others

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF